Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
신장 및 간 장애 환자의 용도 변경 COVID-19 약물 투여에 대한 권장 사항
Review
[키워드] acute infection
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Affect
Altered
Anakinra
anticipated
Antiviral
Atazanavir
available data
Azithromycin
clinician
complex
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 in patient
Dexamethasone
Dosing
drug
drug concentration
drug concentrations
drug interaction
Efficacy
excretion
experimental drug
Experimental drugs
Favipiravir
Guidance
hepatic
hepatic disease
hepatic function
hepatic impairment
Hydroxychloroquine
immune
indications
Injury
interferon beta
Limited
Lopinavir
Lopinavir/ritonavir
medication
medications
metabolism
outbreak
Patient
patients with COVID-19
pharmacokinetic
pharmacokinetics
produced
recommendation
reduced
regimen
Remdesivir
renal
renal or hepatic impairment
respiratory
resulting
ribavirin
Ritonavir
sarilumab
SARS-CoV-2
significantly
therapy
Tocilizumab
toxicities
Toxicity
treat
Treatment
treatment for COVID-19
Trial
University of Liverpool
Variability
was performed
website
[DOI] 10.1007/s40268-020-00333-0 PMC 바로가기 [Article Type] Review
[DOI] 10.1007/s40268-020-00333-0 PMC 바로가기 [Article Type] Review